BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1180 related articles for article (PubMed ID: 9122733)

  • 1. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
    J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma.
    Buzaid AC; Atkins M
    Clin Cancer Res; 2001 Sep; 7(9):2611-9. PubMed ID: 11555571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
    Thompson JA; Gold PJ; Fefer A
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
    Buzaid AC; Legha SS
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):23-8. PubMed ID: 7992096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
    Hofmann MA; Sterry W; Trefzer U
    Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
    Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B
    Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
    J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.